Hope Springs Eternal.
When it comes to stem cell therapy, it could be an eternity.
That’s why GIOSTAR of San Diego is pushing the stem cell research community to act more aggressively to overcome politics and red tape. It is delaying and preventing the United States from taking the lead in the therapeutic applications. “If America is not working aggressively, we will lose out to Asia”, contends Deven Patel, president, CEO and co-founder of the Global Institute of Stem Cell Therapy and Research (GIOSTAR) of La Jolla, California.
Countries like China, Thailand and India have expedited the process of clinical trials required by the United States and forge ahead into treating degenerative diseases, for which stem cell research holds much promise. Biotechnology is growing so fast in China, that within the next decade, it is expected to comprise 60 percent of that country’s growth! Thailand, another center of therapeutic applications, is the one of the few places in the world — Bangkok Hospital — where stem cell therapy has been developed commercially to tackle congestive heart failure.
“If we are going to take too much time, these countries will take the lead,” Deven Patel added – an irony since it has been the United States, the Salk Research Institute, UCSD, UCI, UCLA, Sanford-Bernham and scientists like GIOSTAR’s Chairman and Co-founder Dr. Anand Srivastava who has been associated with these leading universities and research institutions have pioneered the research for more than dozen years and published extensively in revered scientific journals. Dr. Anand Srivastava has an extensive research experience in the field of adult and Embryonic Stem (ES) cell, which is documented by several publications in revered scientific journals. Dr. Anand Srivastava’s expertise and scientific achievements were recognized by many scientific fellowships and by two consecutive award of highly prestigious and internationally recognized, JISTEC award from Science and Technology Agency, Government of Japan. Based on his extraordinary scientific achievements his biography has been included in “WHO IS WHO IN AMERICA” data bank two times, first in 2005 and second in 2010.
Dr. Srivastava says, “While stem cell therapy is on the verge of revolution in parts of Asia, it is still regarded in some U.S. medical circles as risky and under the process of development, principally because of the association with ES cells, whose use has led to a high incidence of tumors and carcinoma”. But research has advanced so much in recent years, that ES cells research has been complemented with the use of induced pluripotent cells (iPSC), Dr. Srivastava added. iPSCs are derived from reprogramming a mature adult cell to give it back the properties of an embryonic stem cell. In order for this adult cell to return to a state of immaturity and be able to differentiate into all cell types. Dr. Srivastava says “the beauty of this science is that clinicians do not need to match the cells for transplant because iPSCs can be generated from a patient own cells, who is seeking for medical treatment”.